Form 4: Oric Pharmaceuticals Director Acquires 35,000 Stock Options
SEC Form 4 Filing
Director Angie You acquires 35,000 stock options in Oric Pharmaceuticals, Inc. on January 2, 2025.
Summary
- Angie You, a director of Oric Pharmaceuticals, Inc., acquired 35,000 stock options on January 2, 2025.
- The exercise price of these options is $8.26.
- The options vest monthly over a year, starting January 2, 2025, and expire on January 1, 2035.
- Following the transaction, Angie You directly owns 35,000 derivative securities.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine disclosure of stock option acquisition by a director. While insider buying can be seen as positive, this is an option grant, which is part of standard compensation.
Positives
- A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership by a company insider. Such filings are common and provide transparency to the market regarding insider transactions.
Key Dates
| Date | Description |
|---|---|
| 01/02/2025 | Date of earliest transaction: Angie You acquired 35,000 stock options. |
| 01/02/2025 | Vesting start date: 1/12th of the shares subject to the option shall vest on each one month anniversary of January 2, 2025. |
| 01/01/2035 | Expiration date of the stock options. |
| 01/06/2025 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.